Faralimomab
Faralimomab is a mouse monoclonal antibody and an immunomodulator.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | Interferon receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
References
- "WHO Drug Information" (PDF). Archived from the original (PDF) on 2011-06-04. Retrieved 2009-09-24.
- Pelletier JP, Mukhtar F (2020). "Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies". In Maitta RW (ed.). Immunologic Concepts in Transfusion Medicine. Philadelphia: Elsevier. p. 286. doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
Cytokine receptor modulators | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemokine |
| ||||||||||||
| CSF |
| ||||||||||||
| Interferon |
| ||||||||||||
| Interleukin |
| ||||||||||||
| TGFβ |
| ||||||||||||
| TNF |
| ||||||||||||
| Others |
| ||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.